Willis S Bowman1, Chad A Newton2, Angela L Linderholm1, Megan L Neely3, Janelle Vu Pugashetti1, Bhavika Kaul4, Vivian Vo1, Gabrielle A Echt1, William Leon1, Rupal J Shah4, Yong Huang5, Christine Kim Garcia6, Paul J Wolters4, Justin M Oldham7. 1. Division of Pulmonary, Critical Care and Sleep Medicine, University of California Davis, Sacramento, CA, USA. 2. Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. 3. Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA. 4. Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California San Francisco, San Francisco, CA, USA. 5. Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, VA, USA. 6. Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Columbia University, New York, NY, USA. 7. Division of Pulmonary, Critical Care and Sleep Medicine, University of California Davis, Sacramento, CA, USA. Electronic address: joldham@ucdavis.edu.
Abstract
BACKGROUND: Progressive fibrosing interstitial lung disease (ILD) is characterised by parenchymal scar formation, leading to high morbidity and mortality. The ability to predict this phenotype remains elusive. We conducted a proteomic analysis to identify novel plasma biomarkers of progressive fibrosing ILD and developed a proteomic signature to predict this phenotype. METHODS: Relative plasma concentrations for 368 biomarkers were determined with use of a semi-quantitative, targeted proteomic platform in patients with connective tissue disease-associated ILD, chronic hypersensitivity pneumonitis, or unclassifiable ILD who provided research blood draws at the University of California (discovery cohort) and the University of Texas (validation cohort). Univariable logistic regression was used to identify individual biomarkers associated with 1-year ILD progression, defined as death, lung transplant, or 10% or greater relative forced vital capacity (FVC) decline. A proteomic signature of progressive fibrosing ILD was then derived with use of machine learning in the University of California cohort and validated in the University of Texas cohort. FINDINGS: The discovery cohort comprised 385 patients (mean age 63·6 years, 59% female) and the validation cohort comprised 204 patients (mean age 60·7 years, 61% female). 31 biomarkers were associated with progressive fibrosing ILD in the discovery cohort, with 17 maintaining an association in the validation cohort. Validated biomarkers showed a consistent association with progressive fibrosing ILD irrespective of ILD clinical diagnosis. A proteomic signature comprising 12 biomarkers was derived by machine learning and validated in the University of Texas cohort, in which it had a sensitivity of 0·90 and corresponding negative predictive value of 0·91, suggesting that approximately 10% of patients with a low-risk proteomic signature would experience ILD progression in the year after blood draw. Those with a low-risk proteomic signature experienced an FVC change of +85·7 mL (95% CI 6·9 to 164·4) and those with a high-risk signature experienced an FVC change of -227·1 mL (-286·7 to -167·5). A theoretical clinical trial restricted to patients with a high-risk proteomic signature would require 80% fewer patients than one designed without regard to proteomic signature. INTERPRETATION: 17 plasma biomarkers of progressive fibrosing ILD were identified and showed consistent associations across ILD subtypes. A proteomic signature of progressive fibrosing ILD could enrich clinical trial cohorts and avoid the need for antecedent progression when defining progressive fibrosing ILD for clinical trial enrolment. FUNDING: National Heart Lung and Blood Institute.
BACKGROUND: Progressive fibrosing interstitial lung disease (ILD) is characterised by parenchymal scar formation, leading to high morbidity and mortality. The ability to predict this phenotype remains elusive. We conducted a proteomic analysis to identify novel plasma biomarkers of progressive fibrosing ILD and developed a proteomic signature to predict this phenotype. METHODS: Relative plasma concentrations for 368 biomarkers were determined with use of a semi-quantitative, targeted proteomic platform in patients with connective tissue disease-associated ILD, chronic hypersensitivity pneumonitis, or unclassifiable ILD who provided research blood draws at the University of California (discovery cohort) and the University of Texas (validation cohort). Univariable logistic regression was used to identify individual biomarkers associated with 1-year ILD progression, defined as death, lung transplant, or 10% or greater relative forced vital capacity (FVC) decline. A proteomic signature of progressive fibrosing ILD was then derived with use of machine learning in the University of California cohort and validated in the University of Texas cohort. FINDINGS: The discovery cohort comprised 385 patients (mean age 63·6 years, 59% female) and the validation cohort comprised 204 patients (mean age 60·7 years, 61% female). 31 biomarkers were associated with progressive fibrosing ILD in the discovery cohort, with 17 maintaining an association in the validation cohort. Validated biomarkers showed a consistent association with progressive fibrosing ILD irrespective of ILD clinical diagnosis. A proteomic signature comprising 12 biomarkers was derived by machine learning and validated in the University of Texas cohort, in which it had a sensitivity of 0·90 and corresponding negative predictive value of 0·91, suggesting that approximately 10% of patients with a low-risk proteomic signature would experience ILD progression in the year after blood draw. Those with a low-risk proteomic signature experienced an FVC change of +85·7 mL (95% CI 6·9 to 164·4) and those with a high-risk signature experienced an FVC change of -227·1 mL (-286·7 to -167·5). A theoretical clinical trial restricted to patients with a high-risk proteomic signature would require 80% fewer patients than one designed without regard to proteomic signature. INTERPRETATION: 17 plasma biomarkers of progressive fibrosing ILD were identified and showed consistent associations across ILD subtypes. A proteomic signature of progressive fibrosing ILD could enrich clinical trial cohorts and avoid the need for antecedent progression when defining progressive fibrosing ILD for clinical trial enrolment. FUNDING: National Heart Lung and Blood Institute.
Authors: Christopher J Ryerson; Eric Vittinghoff; Brett Ley; Joyce S Lee; Joshua J Mooney; Kirk D Jones; Brett M Elicker; Paul J Wolters; Laura L Koth; Talmadge E King; Harold R Collard Journal: Chest Date: 2014-04 Impact factor: 9.410
Authors: Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Milena S Espindola; David M Habiel; Ana Lucia Coelho; Barry Stripp; William C Parks; Justin Oldham; Fernando J Martinez; Imre Noth; David Lopez; Amanda Mikels-Vigdal; Victoria Smith; Cory M Hogaboam Journal: Am J Respir Crit Care Med Date: 2021-02-15 Impact factor: 21.405
Authors: Toby M Maher; Juliet K Simpson; Joanna C Porter; Frederick J Wilson; Robert Chan; Rhena Eames; Yi Cui; Sarah Siederer; Simon Parry; Julia Kenny; Robert J Slack; Jagdeep Sahota; Lyn Paul; Peter Saunders; Philip L Molyneaux; Pauline T Lukey; Gaia Rizzo; Graham E Searle; Richard P Marshall; Azeem Saleem; Arthur R Kang'ombe; David Fairman; William A Fahy; Mitra Vahdati-Bolouri Journal: Respir Res Date: 2020-03-26
Authors: Minna Mononen; Eeva Saari; Hannele Hasala; Hannu-Pekka Kettunen; Sanna Suoranta; Hanna Nurmi; Miia Kärkkäinen; Tuomas Selander; Jukka Randell; Jari Laurikka; Toomas Uibu; Heikki Koskela; Riitta Kaarteenaho; Minna Purokivi Journal: BMC Pulm Med Date: 2022-08-14 Impact factor: 3.320